Inflammation resolution (not suppression)

What actually decides this outcome, in order of size

Resolution is a timed program, not a state, and almost everything on this page assumes the program is currently running. Ranked by how much of the outcome each one owns:

1. Where you are in the time course, because it decides whether there is anything here to act on. Acute injury has an inflammatory phase measured in days and a proliferative phase measured in weeks. A painful tendon at month nine is usually degenerative rather than inflammatory: the cellular infiltrate that pro-resolving lipid mediators act on is largely gone Al-Shaer 2021. Same tendon, same pain, different target, and no product on this page distinguishes them.
2. What is still doing the damage. Resolution cannot finish while the insult continues. A joint that is loaded past tolerance every Thursday, a rotator cuff that is impinged by the way the shelf is reached, an ulcer that is still being irrigated with alcohol. Removing the cause is free and it outranks the entire shelf below it.
3. Whether an anti-inflammatory drug is already in the picture, which is a genuinely two-sided question. A systematic review of NSAID use and soft-tissue and bone healing in the knee found the signal that has worried surgeons for two decades Solaiman 2024, and a separate review of the perioperative evidence argues the clinical case against short courses is weaker than the laboratory case Schug 2021. Both are worth reading before anybody stops a prescribed analgesic on the strength of a supplement page.
4. Whether the pain is nociceptive or neuropathic, because they respond to different halves of this list. Palmitoylethanolamide has been meta-analyzed across double-blind randomized trials in chronic pain, and the effect is not uniform across pain types Lang-Illievich 2023. Buying a mast-cell-directed molecule for a mechanical problem is the commonest miss on this page.
5. The compounds, last, and the best evidenced of them is a kitchen spice with a formulation problem. Curcumin has randomized evidence in osteoarthritis symptoms Daily 2016 and boswellia has a meta-analysis in the same indication Yu 2020. Neither was studied in a healing tendon.

The order to run these in, and what has to be true first

Establish that inflammation is present and still relevant, remove the insult, then choose between the resolution arm and the suppression arm deliberately rather than by buying both.

1. One draw, mainly to be normal. hs-CRP (High-Sensitivity C-Reactive Protein) and ESR (Sed Rate) together answer whether there is a systemic inflammatory signal at all. A localized tendon or a healing incision usually moves neither, and that is the finding: it tells you the problem is local, which changes what is worth taking. Complete Blood Count (CBC) with Differential catches the infection that is masquerading as slow healing.
2. Omega-3 (Fish Oil) or Super EPA (Fish Oil) first, because the substrate has to exist before the mediators can. Resolvins, protectins and maresins are enzymatically derived from eicosapentaenoic and docosahexaenoic acid, so the pro-resolving arm is downstream of dietary supply Al-Shaer 2021. SPMs (Pro-Resolving Mediators) sells the mediators themselves; the substrate is what has the human intake data behind it.
3. Curcumin with a real formulation, or not at all. Unformulated curcumin is poorly absorbed and rapidly conjugated. A phospholipid-complexed curcuminoid mixture was absorbed far better than the standard extract in a comparative study Cuomo 2011, and piperine raises curcumin exposure by inhibiting glucuronidation. The milligrams on the label are not the exposure.
4. Boswellia as the second botanical, judged on the acid content. Boswellic acids are the actives, extracts vary widely in how much of them they contain, and the osteoarthritis meta-analysis was run on standardized material Yu 2020.
5. Palmitoylethanolamide (PEA) if the pain has a neuropathic or mast-cell character. The randomized evidence base exists and has been pooled Lang-Illievich 2023; micronized and ultramicronized preparations are what most trials used, and the unmicronized powder is not the same particle.
6. Low Dose Naltrexone is a prescription question, not a shelf. The strongest single trial is in fibromyalgia rather than in injury Younger 2013, the proposed mechanism is glial rather than peripheral, and it is an opioid antagonist, which matters to anybody holding an opioid prescription.
7. Bromelain and Serrapeptase are the enzymatic arm and they are the weakest link on the page. Bromelain has measurable effects on human endothelial cells in vitro Gwozdzinski 2023; the oral systemic-proteolysis claim is the part that has never been shown. Tart Cherry and Luteolin belong to the same tier, and luteolin's own literature is largely microglial Theoharides 2021.
8. The peptides are last and they are a different argument. KPV, VIP, LL-37 and Thymosin Alpha 1 have real mechanisms and essentially no controlled human data in this indication. Tropisetron is a licensed antiemetic being used for something else.

What gets bought for this that cannot move it

The category that fails here is the one bought to make the swelling go away. Suppression and resolution are opposite instructions to the same tissue. Blocking prostaglandin synthesis removes the signal that recruits the cells that clear the debris, which is the mechanism behind the healing signal seen in the knee review Solaiman 2024; pro-resolving mediators are agonists at receptors that tell those cells to finish and leave Al-Shaer 2021. A reader who takes both is paying for two products to cancel each other, and the one with the better pharmacokinetics wins.

Serrapeptase is the option on this page whose reputation most exceeds what has been demonstrated. The premise is that an orally administered protease survives the gut, enters the circulation intact and degrades fibrin at a site of injury. Each of those three steps is a separate claim, none is supported by human pharmacokinetic data, and the product category has never had to show any of them. Read the enzymatic shelf as a hypothesis with a marketing budget rather than as a treatment arm.

And the commonest reason this page fails is that the reader is nine months late. Chronic tendinopathy is a disorganized-collagen problem with little inflammatory infiltrate; the resolution program has already ended and left the tissue in the wrong state. That reader is buying a fire hose for a building that has already burned, and the honest route is Collagen & matrix synthesis for matrix, Angiogenesis & cytoprotection if perfusion is the limit, and loaded rehabilitation, which is not sold here.

If the picture does not fit, this is the wrong page. A hot, swollen, symmetrical joint pattern is Joints & bone and possibly a clinician rather than a shelf. A fracture is Bone & fracture healing. A gut that is inflamed after anti-inflammatory drugs is Gut lining & mucosal repair. Fever, spreading redness or a wound that smells is an infection and belongs in front of somebody today.

How you would know it was working, on a real read-out and a real timescale

This page makes one prediction that can be wrong. If a pro-resolving intervention is doing the work, function should improve faster than usual on a fixed test while the systemic inflammatory markers stay unremarkable, because the effect is local. If hs-CRP (High-Sensitivity C-Reactive Protein) was high at baseline and falls, something systemic was driving it and the injury was the wrong frame.

• hs-CRP (High-Sensitivity C-Reactive Protein) with ESR (Sed Rate) at baseline, and only repeat them if either was abnormal. These exist here to be normal. A normal pair beside a painful tendon says the process is local, which is a reason to spend on load management rather than on a systemic anti-inflammatory.
• TNF-Alpha only if an autoimmune pattern is in the differential. It is not a monitoring test for a healing ankle, the assay is not standardized across laboratories, and a single value in a well person is uninterpretable.
• F2-Isoprostane / Creatinine (Urine) is the honest oxidative-stress read-out and still not a treatment target. It is a urinary lipid-peroxidation product and it moves with smoking, obesity and acute illness, so a change over eight weeks of a botanical is more likely to be about the rest of your life than about the botanical.
• A fixed provocation test, weekly, on the same day. Single-leg heel raises to failure, grip dynamometry, pain on a 30-second loaded hold. The instrument matters less than never changing it. Pain rated on the worst day produces a curve that only improves.
• 6 to 12 weeks before a verdict, and the number has a reason. Tendon collagen turnover after loading is measured in weeks to months, not days, which is why the osteoarthritis trials behind Daily 2016 and Yu 2020 ran for months rather than for a fortnight. Judging at two weeks measures analgesia.

What will fool you. Almost all acute injury improves on its own and the steepest part of that curve is the fortnight most people start supplementing in. Stopping the aggravating activity at the same time as starting a supplement gives the supplement the credit. An analgesic effect feels like healing and is not: the perioperative review is explicit that pain relief and tissue repair are separate endpoints Schug 2021. And an unformulated curcumin capsule at the same labeled milligrams as a phospholipid complex is a different exposure Cuomo 2011, so a null result on the cheap version says nothing about the trials.

Sources read for these sections

• Solaiman RH. The effect of nonsteroidal anti-inflammatory drug use on soft tissue and bone healing in the knee: a systematic review. Annals of Joint 2024 · PMID 38529297
• Schug SA. Do NSAIDs Really Interfere with Healing after Surgery?. Journal of Clinical Medicine 2021 · PMID 34072128
• Al-Shaer AE. Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition. Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids 2021 · PMID 33794384
• Lang-Illievich K. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients 2023 · PMID 36986081
• Yu G, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies 2020;20(1):225 · PMID 32680575
• Daily JW, et al. Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Medicinal Food, 2016 · PMID 27533649
• Cuomo J, Appendino G, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. Journal of Natural Products 2011 · PMID 21413691
• Younger J. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis and Rheumatism 2013;65(2):529-38 · PMID 23359310
• Theoharides TC, Cholevas C, et al. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. BioFactors 2021 · PMID 33847020
• Gwozdzinski L, et al. The Effect of Diosmin, Escin, and Bromelain on Human Endothelial Cells Derived from the Umbilical Vein and the Varicose Vein: A Preliminary Study.. Biomedicines 2023 · PMID 37371797